Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain.
Level 2 - randomized trial
Placebo-controlled crossover neuroimaging trial in humans
PubMed 25871974 · doi:10.1038/tp.2015.46
What was done
Positron emission tomography (PET) with [11C]raclopride, a dopamine D2/D3 receptor radioligand sensitive to endogenous dopamine, was used to evaluate whether oral caffeine (300 mg) increased striatal dopamine release or altered receptor availability compared with placebo in 20 healthy human controls.
What was found
Caffeine significantly increased D2/D3 receptor availability in the putamen and ventral striatum compared with placebo, while no significant difference was observed in the caudate (specific numerical estimates and p-values were not reported in the abstract). Increases in ventral striatum D2/D3 receptor availability were significantly correlated with caffeine-induced increases in alertness. Because endogenous dopamine release displaces [11C]raclopride and decreases measured availability, the observed increase indicates caffeine does not stimulate striatal dopamine release, but instead increases receptor availability, density, or affinity.
Why it matters
This clarifies caffeine's mechanism of action in the human brain, showing that typical doses promote alertness primarily by modulating D2/D3 receptor availability through adenosine A2A receptor antagonism rather than triggering dopamine release.
Limits
The abstract does not provide exact effect sizes, baseline values, or p-values. The sample size is small (n = 20), tested only healthy controls at a single acute 300 mg dose, and radioligand PET binding cannot fully distinguish between increases in receptor density versus shifts in receptor binding affinity.
Cited by
- supports Caffeine disrupts the adenosine system and upregulates dopamine receptor availability and/or sensitivity in humans.